People with Migraine Reported Significant Improvement When Switching to IV Vyepti After Previous CGRP Therapy Failure

Adults with migraine who previously experienced inadequate response or tolerability to at least 1 preventive calcitonin gene-related peptide (CGRP) antagonist therapy reported clinically meaningful improvements in migraine frequency and patient-reported outcomes after switching to intravenous (IV) treatment with Vyepti (eptinezumab-jjmr; Lundbeck, Valby, Denmark), according to 6-month real-world data from the phase 3 INFUSE clinical trial (NCT04418765). The findings were presented at the 2026 Headache Cooperative of the Pacific (HCOP) Annual Conference and reflect outcomes in a population with high baseline disease burden.

INFUSE is an ongoing, prospective, observational real-world study conducted in the United States through 2 Vyepti Infusion Network partners. The study enrolled adults with migraine who had experienced failure of 1 or more anti-CGRP therapy due to lack of effectiveness or adverse effects, with no protocol-specified washout period required between treatments. The current analysis included participants who completed 6 months of treatment with IV Vyepti (n=111) within the planned 12-month study period. Outcomes were assessed using patient-reported measures, including monthly headache days and global impression of change.

Key findings at 6 months include the following:

• A total of 75.7% of participants reported an improvement of any level in migraine status on the Patient Global Impression of Change scale (95% CI, 66.9% to 82.7%), with 44.1% reporting they were “much improved” or “very much improved” (95% CI, 35.3% to 53.4%).
• Participants experienced a mean reduction of 6.8 monthly headache days (95% CI, 5.2 to 8.3) from 20.0 days per month at baseline, with 44.1% achieving a ≥50% reduction (95% CI, 35.3% to 53.4%).
• A ≥75% reduction in monthly headache days was reported by 26.1% of participants at month 6 (95% CI, 18.9% to 35.0%).
• Participants reported a mean increase of 6.3 additional “good days” per month from 10.0 at baseline (95% CI, 4.7 to 7.9).

Source: Lundbeck. Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti (eptinezumab), at HCOP Annual Conference. Lundbeck. Published January 30, 2026. Accessed January 30, 2026. https://www.lundbeck.com/us/newsroom/2026/lundbeck-presents-new-real-world-data-highlighting-meaningful-im?utm_medium=Earned&utm_source=Media&utm_campaign=NewsRelease&utm_creative=